biotech / news / / The Manila Times
Nxera has achieved a second development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company.
Nxera achieved a second development milestone in its collaboration with Eli Lilly for diabetes drugs.
KEY POINTS
- The milestone validates Nxera’s NxWave platform for identifying small molecule binders to GPCR targets.
- Lilly will now take over further development and commercialization of the identified drug candidates.
- Nxera is eligible for up to US$694 million in milestones plus tiered royalties under the agreement.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →